Blue Earth Diagnostics (United Kingdom)

Recent papers from Blue Earth Diagnostics (United Kingdom)

1. Actinium-225-rhPSMA-10.1 as a novel, alpha-particle-emitting therapy for prostate cancer: results of a preclinical evaluationFrontiers in Oncology · 2026
2. Current practice in reporting internal dosimetry for [177Lu]Lu-DOTATATE therapy: a systematic reviewPhysica Medica · 2026
3. Cities in Transition A Case Study of Urban Population Growth and Spatial Transformation in Begusarai2026
4. Nothing Compares 2 U: Exploring human coach distinctiveness in an age of AIOrganisationsberatung Supervision Coaching · 2026
5. Dosimetry-Driven Alpha Emitter Selection for Radioligand Therapy: Is daughter translocation a significant safety concern?EANM Innovation · 2026
6. Diagnostic performance of ¹⁸ F-flotufolastat PET/CT compared with conventional imaging for detection of pelvic lymph node metastases in men with newly diagnosed prostate cancer: Descriptive post-hoc analysis from the phase 3 LIGHTHOUSE study.Journal of Clinical Oncology · 2026
7. Detection of bone metastases in men with low PSA biochemical recurrence of prostate cancer with ¹⁸ F-flotufolastat PET/CT: A post-hoc analysis from the phase 3 SPOTLIGHT study.Journal of Clinical Oncology · 2026
8. Diagnostic performance of ¹⁸ F-flotufolastat PET/CT compared with conventional imaging in men with biochemical recurrence of prostate cancer: Descriptive post-hoc analysis from the phase 3 SPOTLIGHT study.Journal of Clinical Oncology · 2026
9. An intra-patient contemporaneous comparison of ¹⁸ F-piflufolastat and ¹⁸ F-flotufolastat urinary radioactivity and local and pelvic region detection rates in men with low prostate-specific antigen biochemical recurrence of prostate cancer after radical prostatectomy.Journal of Clinical Oncology · 2026
10. 18F-Fluciclovine for Detection of Recurrent Brain Metastases After Radiotherapy: Image Interpretation Criteria and Diagnostic Performance from the PURSUE StudyInternational Journal of Radiation Oncology*Biology*Physics · 2026
11. An intra-patient contemporaneous comparison of 18F-piflufolastat and 18F-flotufolastat urinary radioactivity and pelvic region detection rates in men with low PSA biochemical recurrence of prostate cancer after radical prostatectomyEuropean Journal of Nuclear Medicine and Molecular Imaging · 2026
12. Toward precision pathology: Deep learning supported fibrosis grading augments performance of international hematopathologists in a large real-world cohortBlood · 2025
13. Multi-endpoint AI morphology model (MEAM) enhances risk prediction for vascular events and disease progression in MPNsBlood · 2025
14. A novel synergistic drug combination of a mitogen-activated extracellular signal-regulated kinase inhibitor with [177Lu]Lu-rhPSMA-10.1 for prostate cancer treatment: Results of a preclinical evaluationNuclear Medicine and Biology · 2025
15. Application of a high-resolution melt assay for monitoring SARS-CoV-2 variants in Burkina Faso and KenyamSphere · 2025
16. Detection Rates of PSMA-PET Radiopharmaceuticals in Recurrent Prostate Cancer: A Systematic ReviewDiagnostics · 2025
17. Organ and tumour dosimetry of 177Lu-rhPSMA-10.1, a novel PSMA-targeted therapy: results from a Phase I trialEuropean Journal of Nuclear Medicine and Molecular Imaging · 2025
18. Preclinical Evaluation of¹⁷⁷Lu-rhPSMA-10.1, a Radiopharmaceutical for Prostate Cancer: Biodistribution and Therapeutic EfficacyJournal of Nuclear Medicine · 2025
19. Head-to-head comparison of anterior nares and nasopharyngeal swabs for SARS-CoV-2 antigen detection in a community drive-through test centre in the UKBMJ Open Respiratory Research · 2025
20. How Standard of Truth Methodology Impacts Diagnostic PSMA-Targeting Radiopharmaceutical Evaluation: Learnings from the Phase 3 SPOTLIGHT StudyDiagnostics · 2025